Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Certara, headquartered in Princeton, NJ, produces model-based pharmaceutical software.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $37.84 |
|---|---|
| 52-week range | $23.00 - $41.79 |
| 50-day moving average | $34.05 |
| 200-day moving average | $29.08 |
| Wall St. target price | $37.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.39 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $37.84 from 2021-10-15
| 1 week (2021-10-08) | 12.45% |
|---|---|
| 1 month (2021-09-16) | 6.74% |
| 3 months (2021-07-16) | 53.88% |
| 6 months (2021-04-16) | 34.85% |
| 1 year (2020-10-12) | N/A |
|---|---|
| 2 years (2019-10-12) | N/A |
| 3 years (2018-10-12) | N/A |
| 5 years (2016-10-12) | N/A |
Valuing Certara stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Certara's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Certara's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.6 million.
The EBITDA is a measure of a Certara's overall financial performance and is widely used to measure a its profitability.
To put Certara's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $261.8 million |
|---|---|
| Gross profit TTM | $142.8 million |
| Return on assets TTM | -1.18% |
| Return on equity TTM | -7.52% |
| Profit margin | -21.02% |
| Book value | $5.46 |
| Market capitalisation | $5.3 billion |
TTM: trailing 12 months
There are currently 2.1 million Certara shares held short by investors – that's known as Certara's "short interest". This figure is 6.4% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Certara shares can be evaluated.
Certara's "short interest ratio" (SIR) is the quantity of Certara shares currently shorted divided by the average quantity of Certara shares traded daily (recently around 1.4 million). Certara's SIR currently stands at 1.56. In other words for every 100,000 Certara shares traded daily on the market, roughly 1560 shares are currently held short.
To gain some more context, you can compare Certara's short interest ratio against those of similar companies.
However Certara's short interest can also be evaluated against the total number of Certara shares, or, against the total number of tradable Certara shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Certara's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Certara shares in existence, roughly 10 shares are currently held short) or 0.0249% of the tradable shares (for every 100,000 tradable Certara shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Certara.
Find out more about how you can short Certara stock.
We're not expecting Certara to pay a dividend over the next 12 months.
You may also wish to consider:
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.